Dimeric prodrug-based nanomedicines for cancer therapy.
With the rapid development of conjugation chemistry and biomedical nanotechnology, prodrug-based nanosystems (PNS) have emerged as promising drug delivery nanoplatforms. Dimeric prodrug, as an emerging branch of prodrug, has been widely investigated by covalently conjugating two same or different drug molecules. In recent years, great progress has been made in dimeric prodrug-based nanosystems (DPNS) for cancer therapy. Many advantages offered by DPNS have significantly facilitated the delivery efficiency of anticancer drugs, such as high drug loading capacity, favorable pharmacokinetics, tumor stimuli-sensitive drug release and facile combination theranostics. Given the rapid developments in this field, we here outline the latest updates of DPNS in cancer treatment, focusing on dimeric prodrug-encapsulated nanosystems, dimeric prodrug-nanoassemblies and tumor stimuli-responsive DPNS. Moreover, the design principle, advantages and challenges of DPNS for clinical cancer therapy are also highlighted.
['Li|Shumeng|S|', 'Shan|Xinzhu|X|', 'Wang|Yuequan|Y|', 'Chen|Qin|Q|', 'Sun|Jin|J|', 'He|Zhonggui|Z|', 'Sun|Bingjun|B|', 'Luo|Cong|C|']
D000970:Antineoplastic Agents D016503:Drug Delivery Systems D065546:Drug Liberation D050997:Nanomedicine D009369:Neoplasms D011355:Prodrugs
Nanomedicine Cancer therapy Conjugation chemistry Biomedical nanotechnology Dimeric prodrug